Continued progress in biomarker-driven strategies and rational combination therapies is expected to further refine personalized treatment approaches and improve outcomes for patients with advanced liposarcoma.

6 days ago

Review • Journal • IO biomarker

MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

Xpovio (selinexor) • eribulin mesylate • Yondelis (trabectedin)

A Trial to Study the Influence of Ultrasound Guidance on the Complications of Central Catheter (clinicaltrials.gov)

P=N/A, N=264, Terminated, Centre Hospitalier Universitaire, Amiens | Unknown status --> Terminated; Recruitment difficulties

7 days ago

Trial termination

21d

The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (clinicaltrials.gov)

P=N/A, N=114, Recruiting, Guy's and St Thomas' NHS Foundation Trust | Not yet recruiting --> Recruiting

21 days ago

Enrollment open

23d

Autophagy-centered gene networks reveal prognostic biomarkers and therapeutic targets in esophageal cancer. (PubMed, Discov Oncol)

Screening for drugs also revealed AKT1, TP53, and PIK3R4 as druggable hubs, and many drugs (e.g., Everolimus, Dabrafenib, Trabectedin) showing high-affinity interactions. The study discovers new prognostic markers (ATG4A, GABARAPL2, GAPDH) and druggable targets, which could lead to better risk stratification and smarter drug repurposing. While restricted to in silico analyses, the integrative approach provides a basis for subsequent laboratory confirmation and translational development.

23 days ago

Journal

TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • ATG5 (Autophagy Related 5) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • AMBRA1 (Autophagy And Beclin 1 Regulator 1) • ATG12 (Autophagy Related 12) • ATG3 (Autophagy Related 3) • ATG7 (Autophagy Related 7) • GABARAPL2 (GABA Type A Receptor Associated Protein Like 2)

Tafinlar (dabrafenib) • everolimus • Yondelis (trabectedin)

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) (clinicaltrials.gov)

P2, N=102, Active, not recruiting, Oregon Health and Science University | Trial completion date: Mar 2026 --> Oct 2026

1 month ago

Trial completion date

2ms

Betadine vs Sterile Water for Periurethral Preparation (clinicaltrials.gov)

P4, N=148, Recruiting, University of Louisville | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

2ms

Linezolid Dosing Strategies in Drug-Resistant TB (clinicaltrials.gov)

P2, N=138, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed

2 months ago

Trial completion

CD4 (CD4 Molecule)

2ms

Clinical Study of Etoposide Soft Capsules Combined with Immune Checkpoint Inhibitors as Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer without Disease Progression After First-Line Chemoimmunotherapy (ChiCTR2600119676)

P=N/A, N=49, Army Medical Center of PLA; Army Medical Center of PLA

2 months ago

New trial • Checkpoint inhibition

etoposide oral

2ms

Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. (PubMed, Nat Med)

Here we provide the basis for further development of trabectedin/irinotecan for patients with ES by the international cooperative groups. ClinicalTrials.gov: NCT04067115 .

2 months ago

P1/2 data • Journal

FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)

irinotecan • Yondelis (trabectedin)

2ms

Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity (clinicaltrials.gov)

P=N/A, N=13, Completed, West Virginia University | Recruiting --> Completed | N=20 --> 13

2 months ago

Trial completion • Enrollment change

2ms

DRAMATIC: Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (clinicaltrials.gov)

P2, N=271, Active, not recruiting, Boston University | Recruiting --> Active, not recruiting